Executive Moves | Healthcare | BioTuesdays by Kilmer Lucas IR

Executive Moves

Candel appoints Mark Sims as CCO

Candel Therapeutics (NASDAQ: CADL) has announced the appointment of Mark Sims as its chief commercial officer (CCO), effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for...

June 25, 2026

Executive Moves

Dr. Jeff Coller joins 4basebio’s SAB

4basebio (AIM: 4BB) has appointed Jeff Coller, PhD, to its strategic advisory board (SAB). Dr. Coller is a globally recognized expert in mRNA biology and translation. According to 4basebio, his understanding of...

June 15, 2026

Executive Moves

Tempest appoints Drake Richey and Dr. John Yee to BoD

Tempest Therapeutics (NASDAQ: TPST) has appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its board of directors (BoD), effective June 4, 2026. Mr. Richey and Dr. Yee collectively bring decades...

June 5, 2026

Executive Moves

Cocrystal appoints James Sapirstein as CEO

Cocrystal Pharma (NASDAQ: COCP) has appointed biopharma industry leader James Sapirstein as chief executive officer (CEO), effective immediately. According to Cocrystal, Mr. Sapirstein will also be appointed to its...

June 4, 2026

Executive Moves

Dr. John Lambert joins Defence BoD

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. John Lambert to its board of directors (BoD), effective immediately. Internationally recognized, Dr. Lambert brings more than four decades of...

June 1, 2026

Executive Moves

Former FDA official Peter J. Pitts joins BrainStorm BoD

BrainStorm Cell Therapeutics (OTCQB: BCLI) has appointed former FDA associate commissioner, Peter J. Pitts, to its board of directors (BoD), effective immediately. Mr. Pitts is a globally recognized expert in healthcare...

May 28, 2026

Executive Moves

Immunic appoints Michael W. Bonney as BoD chair

Immunic (NASDAQ: IMUX) has announced the appointment of biopharmaceutical executive Michael W. Bonney as chair of its board of directors (BoD), effective May 16, 2026. Simona Skerjanec, MPharm, MBA, will transition from...

May 19, 2026

Executive Moves

ARS appoints Donn Casale as president

ARS Pharmaceuticals (NASDAQ: SPRY) has appointed Donn Casale as president, effective June 1, 2026, with Richard Lowenthal continuing to lead as CEO. Mr. Casale brings 25 years of biopharmaceutical commercial leadership...

May 13, 2026

Executive Moves

BetterLife appoints Doug Drysdale as executive chairman and director

BetterLife Pharma (CSE: BETR; OTCQB: BETRF; FSE: NPAU) has appointed its current corporate advisor, Doug Drysdale, as executive chairman and director. Mr. Drysdale was formerly CEO of Cybin (NYSE: CYBN) where he led the...

May 13, 2026

Executive Moves

Dr. Kyle Bauser joins Titan Partners as Director, Senior Research Analyst

Investment bank Titan Partners has announced that Kyle Bauser, Ph.D., has been appointed Director, Senior Research Analyst covering healthcare technologies. Dr. Bauser brings more than 12 years of experience in equity...

May 12, 2026

Executive Moves

Lindsay Hamelin joins Restart’s BoD

Restart Life Sciences (CSE: HEAL; FSE: HN30; OTC Pink: NMLSF) has announced the appointment of capital markets veteran, Lindsay Hamelin, as an independent director on its board of directors (BoD), effective immediately...

May 7, 2026

Executive Moves

Nancy Saitta and Leilani Bradford join Planet 13’s BoD

Planet 13 Holdings (CSE: PLTH; OTCQX: PLNH) has announced the appointments of the Honorable Nancy Saitta and Leilani Bradford as independent directors, filling two newly created seats on its board of directors (BoD)...

May 5, 2026

Executive Moves

Eupraxia appoints Dr. Jeymi Tambiah as CMO

Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has announced the appointment of Jeymi Tambiah, MB ChB, FRCS, MS, FAPCR, FFPM, as chief medical officer (CMO), and the retirement of the current CMO, Dr. Mark Kowalski...

May 4, 2026

Executive Moves

Piper Sandler adds Dr. Patrick McCormick to healthcare investment banking team

Investment bank, Piper Sandler, has announced the appointment of Patrick McCormick, MD, as a managing director in its healthcare investment banking group. Dr. McCormack will be based in San Francisco and focused on...

April 30, 2026

Executive Moves

Kunal Bhatia joins Strand as CFO

Closely held Strand Therapeutics has announced the appointment of Kunal Bhatia as chief financial officer (CFO). Mr. Bhatia brings 15 years of investment banking experience leading fundraising, business development, and...

April 30, 2026

Executive Moves

Inventiva builds C-suite ahead of Phase 3 MASH readout

Inventiva (Euronext Paris and NASDAQ: IVA) has appointed three new members to its leadership team, including Axel-Sven Malkomes as chief financial officer, Susan Coles as chief legal officer, and Pamela Herbster as...

April 27, 2026

Executive Moves

Orlando Oliveira joins Santhera as CEO

Santhera Pharmaceuticals (SIX: SANN) has appointed Orlando Oliveira as chief executive officer (CEO), succeeding Dario Eklund, effective July 15, 2026. With more than 25 years of global experience across specialty...

April 27, 2026

Executive Moves

Dr. Ingrid Müller joins Evotec as COO

Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT) has appointed Dr. Ingrid Müller as Chief Operating Officer (COO), effective May 1, 2026. Dr. Müller brings to the role more than 20 years of international leadership...

April 15, 2026

Executive Moves

Prelude appoints Dr. Charles Morris as CMO

Prelude Therapeutics (NASDAQ: PRLD) has appointed Dr. Charles Morris as chief medical officer (CMO), effective April 20, 2026. Dr. Morris is a medical oncologist with more than 30 years of oncology drug development...

April 15, 2026

Executive Moves

OS appoints Moderna co-founder Dr. Robert S. Langer as strategic advisor

OS Therapies (NYSE American: OSTX) has appointed Robert S. Langer, PhD, and co-founder of Moderna, to its strategic advisory board. According to OS, Dr. Langer will assist management with prioritizing the listeria...

April 13, 2026

Executive Moves

Evotec appoints Dr. Ashiq H. Khan as CCO

Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT) has appointed Dr. Ashiq H. Khan as EVP global head, chief commercial officer (CCO). Dr. Khan brings more than 15 years of international leadership experience in...

April 1, 2026

Executive Moves

Dr. Raj S. Pruthi joins PreveCeutical’s BOD

PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF; FSE: 18H0) has appointed Raj S. Pruthi, MD, MHA, FACS, to its board of directors (BOD). Dr. Pruthi currently serves as CMO of Relmada Therapeutics. An accomplished...

March 30, 2026

Subscribe